Annexon Biosciences

In July 2020, Annexon Biosciences announced a Series C round financing of $100 million. Annexon Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of therapies for patients with complement-mediated autoimmune and neurodegenerative disorders.